Caroline Springer - Profile
Professor Caroline Springer leads the Gene and Oncogene Targeting team within the Cancer Therapeutics Section at The Institute of Cancer Research. Her work focuses on drug development.
She is currently investigating several potential drugs, including antibody directed enzyme prodrug therapy, gene directed enzyme producing therapy and new therapies for malignant melanoma. Other tumour types she examines include hepatoma, colorectal carcinoma and head and neck cancer. Professor Springer’s research also involves developing different drug classes that stop tumour cells being in a state of continued growth.
Professor Springer was first touched by cancer as a seven-year-old when her grandmother died of colorectal cancer. She now feels lucky to have a job that is both interesting a rewarding.
"It’s great to be in a position to try to make a real difference. Our aim is to develop novel therapies that can benefit people. It is something worth pursuing day and night."
After completing a PhD in biological chemistry and an MRC Postdoctoral Fellowship at Imperial College School of Medicine, Professor Springer was awarded a Cancer Research UK grant to develop ADEPT (antibody-directed enzyme prodrug therapy) as a therapy for colorectal carcinoma treatment at the ICR.
In her spare time Professor Springer likes to visit galleries and museums and to bake and ice novelty cakes.
